ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos211.4 M258.4 M249.5 M221.5 M233 M962.4 MInvestigación y desarrollo27.8 M26.7 M22 M24.9 M21.8 M95.4 MBeneficio operativo114.2 M46.9 M45.4 M72.6 M-1.29 B-1.12 BTotal de ingresos no operativos600 K400 K-2.6 M-9.6 M-1.4 M-13.2 MGastos por intereses, netos de intereses capitalizados8 M2.3 M2.3 M2.4 M2.5 M9.5 MIngresos no operativos, una vez deducidos los gastos por intereses-8 M-2.3 M-2.3 M-2.4 M-2.5 M-9.5 MIngresos/gastos extraordinarios600 K400 K-2.6 M-9.6 M-1.4 M-13.2 MBeneficio antes de impuestos70.1 M8.3 M3.2 M22.4 M-1.33 B-1.3 BParticipación en los beneficios-300 K-100 K-400 K-200 K-33.6 M-34.3 MImpuestos111.6 M8.2 M3.7 M9.7 M82.8 M104.4 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas-41.5 M100 K-500 K12.7 M-1.41 B-1.4 BOperaciones suspendidas-2.9 M-6.5 M-7.9 M-5.2 M-3.5 M-23.1 MBeneficio neto-44.4 M-6.4 M-8.4 M7.5 M-1.42 B-1.43 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-44.4 M-6.4 M-8.4 M7.5 M-1.42 B-1.43 BBeneficio básico por acción-0.32-0.05-0.060.05-10.23-10.29Beneficio por acción diluido-0.32-0.05-0.060.05-10.23-10.29Número medio de acciones ordinarias137.4 M137.7 M138.2 M138.5 M138.5 M552.9 MAcciones diluidas137.4 M137.7 M138.2 M138.9 M138.5 M553.3 MEBITDA194.5 M126.8 M131.7 M158 M-1.2 B-784.7 MEBIT114.2 M46.9 M45.4 M72.6 M-1.29 B-1.12 BCosto de los ingresos752.4 M651.6 M693.4 M666.2 M747.4 M2.76 BOtros costes de producción——————Amortización y depreciación (flujo de caja)80.3 M79.9 M86.3 M85.4 M85.9 M337.5 M
Perrigo Company plc
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.